Treatment of hepatic hydatid disease with mebedazole: preliminary results in four cases.
Mebendazole was given to four patients with hepatic hydatid disease. In three patients hydatidosis had remained after surgery, and in the fourth it could not be treated surgically. Mebendazole was given orally in maximum doses of 400-600 mg three times a day during courses lasting 21 to 30 days. Ultrasonic echotomography showed a complete regression of the intrahepatic cysts after four to 13 months in all four cases. In three patients the course of treatment had to be repeated. Mebendazole also induced clinical improvement and a progressive lowering of the concentration of specific IgE of Echinococcus granulosus. During treatment circulating blood levels of specific immune complexes of antigen 5 were increased. These observations indicate that mebendazole has a lethal effect on E granulosus cysts in primary hydatid disease in man and that the efficacy of chemotherapy can be assessed with ultrasonography and by measuring changes in the concentration of specific IgE of E granulosus and circulating immune complexes.
D000328:Adult; D000936:Antigen-Antibody Complex; D001562:Benzimidazoles / Q000627:therapeutic use*; D004444:Echinococcosis, Hepatic / Q000188:drug therapy* / Q000276:immunology; D005260:Female; D006801:Humans; D007073:Immunoglobulin E / Q000032:analysis; D008297:Male; D008463:Mebendazole / Q000627:therapeutic use*; D008875:Middle Aged; D014054:Tomography / Q000379:methods; D014463:Ultrasonography
D000936:Antigen-Antibody Complex; D001562:Benzimidazoles; D007073:Immunoglobulin E; D008463:Mebendazole